iShares Genomics Immunology and Healthcare ETF (NYSEARCA:IDNA) Short Interest Down 86.5% in December

iShares Genomics Immunology and Healthcare ETF (NYSEARCA:IDNA) was the target of a significant decline in short interest in December. As of December 31st, there was short interest totaling 1,277 shares, a decline of 86.5% from the December 15th total of 9,491 shares. Currently, 0.0% of the company’s shares are short sold. Based on an average daily trading volume, of 17,516 shares, the days-to-cover ratio is presently 0.1 days. Based on an average daily trading volume, of 17,516 shares, the days-to-cover ratio is presently 0.1 days. Currently, 0.0% of the company’s shares are short sold.

iShares Genomics Immunology and Healthcare ETF Stock Up 2.4%

Shares of NYSEARCA:IDNA traded up $0.68 during trading on Wednesday, reaching $28.55. The stock had a trading volume of 16,495 shares, compared to its average volume of 42,499. The stock has a market cap of $142.75 million, a P/E ratio of 14.76 and a beta of 1.07. The business has a fifty day moving average price of $26.59 and a 200-day moving average price of $24.14. iShares Genomics Immunology and Healthcare ETF has a fifty-two week low of $17.26 and a fifty-two week high of $28.59.

Institutional Investors Weigh In On iShares Genomics Immunology and Healthcare ETF

A number of hedge funds and other institutional investors have recently made changes to their positions in IDNA. Portland Global Advisors LLC acquired a new position in iShares Genomics Immunology and Healthcare ETF in the second quarter valued at $2,099,000. Flow Traders U.S. LLC acquired a new stake in shares of iShares Genomics Immunology and Healthcare ETF in the second quarter worth approximately $931,000. Ameriprise Financial Inc. grew its holdings in iShares Genomics Immunology and Healthcare ETF by 8.4% in the third quarter. Ameriprise Financial Inc. now owns 71,473 shares of the company’s stock valued at $1,688,000 after purchasing an additional 5,540 shares during the period. Finally, Triumph Capital Management acquired a new position in iShares Genomics Immunology and Healthcare ETF during the third quarter worth approximately $35,000.

iShares Genomics Immunology and Healthcare ETF Company Profile

The iShares Genomics Immunology and Healthcare ETF (IDNA) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund tracks a market-cap-selected and -weighted index of global stocks involved in genomics, immunology, and bioengineering. IDNA was launched on Jun 11, 2019 and is managed by BlackRock.